Literature DB >> 2988023

Leukotrienes C4 and D4 in psoriatic skin lesions.

S D Brain, R D Camp, A K Black, P M Dowd, M W Greaves, A W Ford-Hutchinson, S Charleson.   

Abstract

Chemoattractant arachidonate lipoxygenase products have been recovered from the skin lesions of psoriasis, and may play a role in eliciting the intra-epidermal neutrophil infiltrate that characterises this disease. In view of evidence for lipoxygenase activity in psoriasis, the characteristic vasodilation in psoriatic lesions, and the vasodilator properties of leukotriene (LT) C4 and D4 in human skin, the presence of these LTs in psoriatic lesions has been investigated. Skin chamber fluid from abraded psoriatic lesions contained significantly greater amounts of immunoreactive material than that from clinically normal skin, as determined by a double antibody radioimmunoassay (RIA) that uses antiserum cross-reacting with both LTC4 and LTD4. Purification of lesional chamber fluid and scale extracts by high performance liquid chromatography (HPLC) and RIA of fractions showed immunoreactivity which co-eluted with standard LTC4 and LTD4. These findings suggest that LTC4 and LTD4 may play a role in mediating the vasodilation and increased blood flow that characterise psoriatic skin lesions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988023     DOI: 10.1016/0090-6980(85)90084-x

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  7 in total

1.  Heterogeneous distribution of lipoxygenase products in psoriatic skin lesions.

Authors:  K Fogh; J Kiil; T Herlin; T Ternowitz; K Kragballe
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

Review 2.  Leukotrienes in inflammation.

Authors:  M A Bray
Journal:  Agents Actions       Date:  1986-10

3.  In vitro inhibition of leukotriene B4 formation by exogeneous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils.

Authors:  K Fogh; T Herlin; K Kragballe
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

4.  Percutaneous absorption and metabolism of lonapalene in psoriatic skin.

Authors:  P A Lehman; R V Tomlinson; J I Johnson; J E Olerud; W A Akers; T J Franz
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

5.  Platelet activating factor (PAF) and lyso-PAF in psoriasis.

Authors:  M R Judge; R M Barr; A I Mallet; F Courtney; A Kobza Black; M W Greaves
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

6.  Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism.

Authors:  L Iversen; P Kristensen; B Grøn; V A Ziboh; K Kragballe
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

7.  The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin.

Authors:  R M Barr; A K Black; P M Dowd; O Koro; K Mistry; J L Isaacs; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.